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Summary
8p11 myeloproliferative syndrome (EMS) is a hematopoietic stem cell disorder characterized by myeloid hyperplasia and
non-Hodgkin’s lymphoma with chromosomal translocations fusing several genes, most commonly ZNF198, to fibroblast
growth factor receptor-1 (FGFR1). However, patients with BCR-FGFR1 fusion present with typical chronic myeloid leukemia
(CML). We demonstrate that ZNF198-FGFR1 induces EMS-like disease in mice, with myeloproliferation and T lymphoma
arising from common multipotential progenitors. Mutation of FGFR1 Tyr766 attenuates both myeloid and lymphoid diseases,
identifying phospholipase C-1 as a downstream effector. Bcr-FGFR1 binds Grb2 via Bcr Tyr177 and induces CML-like
leukemia in mice, whereas Bcr-FGFR1/Y177F lacks Grb2 binding and causes EMS-like disease. These results implicate
different signaling pathways originating from both kinase and fusion partner in the pathogenesis of CML and EMS.
Introduction lar drug targets. An animal model also provides an avenue to
study the pathophysiology of the disease and a platform for
The concept of molecularly targeted therapy for cancer became developing and testing targeted therapies.
reality with the introduction of imatinib mesylate (Gleevec, for- The 8p11 myeloproliferative syndrome (EMS, also known
merly STI-571) for the treatment of chronic myeloid leukemia as stem cell leukemia/lymphoma syndrome) is a distinct hema-
(CML). Imatinib is a small molecule inhibitor of the Abl, platelet- tologic disorder characterized by myeloid hyperplasia, eosino-
derived growth factor  receptor, and Kit tyrosine kinases that philia, and lymphoblastic lymphoma associated with balanced
is remarkably effective for induction of hematologic and cytoge- chromosomal translocations involving 8p11 (Inhorn et al., 1995;
netic remissions in chronic phase CML patients (Kantarjian et Macdonald et al., 1995). The myeloid hyperplasia has some
al., 2002). The rationale for targeting Abl in CML came in part similarity to CML, with overproduction of myeloid cells that
retain the capacity to differentiate, but lacks basophilia andfrom the demonstration that expression of the BCR-ABL fusion
gene in bone marrow caused fatal myeloproliferative disease in tends to progress to acute myeloid leukemia within 1 to 2 years
of diagnosis. About 70% of EMS patients present with or de-mice that closely resembled CML (Daley et al., 1990), implicating
the Bcr-Abl tyrosine kinase as the direct cause of CML. The velop high-grade non-Hodgkin’s lymphoblastic lymphoma, pre-
dominantly of a primitive T cell phenotype. Both myeloid andsuccess of imatinib in CML illustrates that development of accu-
rate animal models for other human leukemias will be an impor- lymphoma cells share the 8p11 translocation, demonstrating
that the disease originates from a hematopoietic stem cell. Thetant step in the identification and validation of potential molecu-
S I G N I F I C A N C E
Tyrosine kinases are increasingly important targets for the development of drugs for treatment of hematologic malignancies and
solid tumors, but monotherapy with kinase inhibitors may lead to resistance. Using a mouse retroviral bone marrow transplant model,
we demonstrate that the ZNF198-FGFR1 fusion kinase is the direct cause of human 8p11 myeloproliferative syndrome, validating it
as a therapeutic target, and identify phospholipase C- as a critical downstream pathway whose blockade may complement kinase
inhibitor therapy. In contrast, the Bcr-FGFR1 fusion kinase from patients with t(8;22) induces chronic myeloid leukemia-like disease
through a pathway involving Grb2. This model system will be useful for further studies of the pathophysiology of 8p11 syndrome and
for developing and testing molecularly targeted therapies.
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Figure 1. ZNF198-FGFR1 induces distinct MPD in mice
A: Schematic of (top to bottom) c-Abl, p210 Bcr-Abl, ZNF198, FGFR1, and ZNF198-FGFR1 polypeptides, including ZNF198-FGFR1 kinase-inactive (K514R) and
PLC-1 binding site (Y766F) mutants. Domains indicated by gray boxes include SH3, SH2, kinase, DNA binding, and actin binding domains in Abl, coiled-
coil (CC) domain, Tyr177 Grb2 binding site, and Dbl/Cdc42 homology domain in Bcr, zinc finger (MYM) repeats (Reiter et al., 1998) and proline-rich (P)
dimerization domain (Xiao et al., 2000) in ZNF198, and extracellular Ig repeats, transmembrane (TM) domain, split kinase domain, and seven intracellular
tyrosine autophosphorylation sites (Mohammadi et al., 1996) in FGFR1 (numbered according to their position in normal FGFR1). The point of fusion is indicated
by the vertical dotted line.
B: Kaplan-Meier-style survival curve for recipients of bone marrow transduced with BCR-ABL (red, n  13), ZNF198-FGFR1 (magenta, n  26), ZNF198-FGFR1
Y766F mutant (blue, n  11), and ZNF198-FGFR1 kinase-inactive (k.i.) mutant (green, n  5). The difference in survival between any of the individual arms
is highly significant (p  0.0001, Mantel-Cox test).
C: Flow cytometric plots of peripheral blood (PB, in red), spleen (in green), and mesenteric lymph node/Peyer’s patch cells (mes/PP, blue) from a
representative mouse transplanted with ZNF198-FGFR1-transduced marrow, sacrificed 42 days posttransplant with a peripheral blood leukocyte count of
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Table 1. Clinicopathological features of leukemias induced by fusion tyrosine kinases
Median Liver T lymphoma
survival PB WBCa Spleen histiocytic Lung myeloid
Oncogene (days) (death) weight (g) infiltrates infiltration/hemorrhage Intestine Thymus
p210 BCR-ABL 17 326  79 0.80  0.03    
ZNF198-FGFR1 42 44  21b 0.36  0.05b    
ZNF198-FGFR1 Y766F 116 27  15 0.49  0.12    
BCR-FGFR1 14 220  55 0.39  0.02    
BCR-FGFR1 Y177F 39 12  4c 0.30  0.03    
, present; , extensive; , absent.
a Peripheral blood leukocyte count.
b Significantly different from corresponding BCR-ABL values (p  0.001, unpaired t test).
c Significantly different from BCR-FGFR1 (p  0.01, unpaired t test).
translocation partner can be derived from several different chro- 2000), suggesting that FGFR1 fusion partners induce constitu-
tive FGFR1 tyrosine kinase activity through self-association,mosomes including 6q27, 9q33, 11p15, 12q15, 13q12, 17q25,
and 19q13 (Macdonald et al., 2002). analogous to the activation of Abl by the coiled-coil oligomeriza-
tion domain in Bcr. Studies in Ba/F3 cells demonstrate that inThe breakpoint of the most common EMS-associated trans-
location, t(8;13)(p11;q12), was molecularly cloned in 1998 and contrast to Bcr-Abl, ZNF198-FGFR1 and Bcr-FGFR1 are resis-
tant to imatinib but sensitive to a specific FGFR1 kinase inhibitorshown to fuse a novel gene on 13q12, ZNF198 (also called FIM
or RAMP), to the fibroblast growth factor receptor-1 (FGFR1) (Smedley et al., 1999). Otherwise, no significant differences in
oncogenic activity between Bcr-Abl and the various FGFR1gene on 8p11 (Popovici et al., 1998; Reiter et al., 1998; Smedley
et al., 1998; Xiao et al., 1998). Subsequently, breakpoints of the fusion kinases have been identified.
An understanding of the pathogenesis of leukemias associ-t(6;8), t(8;9), and t(8;19) translocations were identified and found
to fuse the FOP gene on 6q27 (Popovici et al., 1999), the CEP110 ated with activated forms of FGFR1 requires expression of 8p11
fusion genes in the hematopoietic system. Here, we tested thegene on 9q33 (Guasch et al., 2000), and an endogenous human
retroviral sequence on 19q13 (Guasch et al., 2003), respectively, leukemogenic activity of ZNF198-FGFR1 and BCR-FGFR1 on-
cogenes in a murine bone marrow transduction/transplantationto FGFR1. The resulting chimeric genes produce fusions of
distinct amino-terminal partner proteins with the cytoplasmic model system. We demonstrate that ZNF198-FGFR1 and BCR-
FGFR1 induce distinct hematologic disease in mice throughtyrosine kinase domain of FGFR1. Recently, several patients
with t(8;22) have been described with 8p11 translocations in- different signaling pathways originating from both the partner
protein and the kinase domain.volving the BCR gene on 22q11, identifying Bcr as a fifth fusion
partner for FGFR1 (Demiroglu et al., 2001; Fioretos et al., 2001).
Interestingly, these patients present with myeloproliferative dis- Results
ease and basophilia but without lymphoma, and hence more
closely resemble typical Ph CML rather than EMS, suggesting ZNF198-FGFR1 induces myeloproliferative disease
that the leukemia phenotype might be influenced by the identity and T lymphoma in mice
of the FGFR1 fusion partner. We transduced bone marrow from 5-fluorouracil-treated Balb/c
The ZNF198 gene is ubiquitously expressed and encodes donor mice with retrovirus coexpressing fusion tyrosine kinases
a protein with five novel zinc finger repeats that is localized to (Figure 1A) and green fluorescent protein (GFP) via an internal
the cell nucleus and nucleolus (Ollendorff et al., 1999). The ribosome entry site (Schwaller et al., 1998), and transplanted the
ZNF198-FGFR1 and Bcr-FGFR1 fusion proteins are cytoplasmi- marrow into lethally irradiated syngeneic recipient mice. As de-
cally localized, constitutively active tyrosine kinases that trans- scribed previously (Li et al., 1999), recipients of marrow transduced
with p210 BCR-ABL developed rapidly fatal myeloproliferative dis-form Ba/F3 cells to become independent of interleukin-3 for
survival and proliferation (Demiroglu et al., 2001; Ollendorff et ease (MPD) resembling human CML (Figure 1B and Table 1), with
massive expansion of maturing myeloid cells and infiltration ofal., 1999; Popovici et al., 1998; Smedley et al., 1999; Xiao et
al., 1998). ZNF198-FGFR1 transforming activity requires a novel spleen, liver, and lungs (Million et al., 2002, and data not shown).
In contrast, recipients of ZNF198-FGFR1-transduced marrowproline-rich oligomerization domain in ZNF198 (Xiao et al.,
53.2  103/	l and spleen weight of 0.33 g. Cells were stained with PE-conjugated (y axis) isotype control antibody (iso) or antibodies against Mac-1, B220,
or Thy-1. Expression levels of GFP are shown along the x axis; cells from an untransplanted Balb/c mouse were localized to the left lower quadrant (
99%,
data not shown). Note GFP spleen cells expressing B220 or Thy-1 indicative of multilineage repopulation.
D–G: Chronic MPD in recipients of ZNF198-FGFR1-transduced marrow. D: Wright-Giemsa-stained peripheral blood with several eosinophils (arrowheads). E:
Hematoxylin and eosin (H&E)-stained spleen. F: H&E-stained liver. G: H&E-stained lung. Scale bars: 10 	m (D), 20 	m (E and F), 100 	m (G).
H: Survival curve of primary recipients of ZNF198-FGFR1-transduced bone marrow (magenta, n  18) and of lethally irradiated secondary recipients of BM
and/or spleen from these diseased primary mice (black, n  14). The majority of secondary recipients had evidence of chronic MPD and succumbed to
T lymphoma. Pairs of recipients transplanted with cells from the same primary donor are indicated by numbers. The animal indicated by the asterisk died
on day 17 posttransplant with pancytopenia and likely failed to engraft.
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survived significantly longer (Figure 1B) and succumbed to dis-
tinct disease (Table 1). All ZNF198-FGFR1 recipients developed
MPD as evidenced by leukocytosis, splenomegaly, and increased
GFP Mac-1 cells in peripheral blood, spleen, and bone mar-
row (Figure 1C and data not shown), but the circulating myeloid
cells were more mature than in BCR-ABL-induced MPD (Li et
al., 2001b), with few myelocytes and promyelocytes (Figure 1D).
About 20% (9/44) of ZNF198-FGFR1 recipients had eosinophilia
(defined as 
5% eosinophils in peripheral blood or bone mar-
row), while eosinophilia was not observed in BCR-ABL recipi-
ents (Li et al., 2001b) (and data not shown). Spleens demon-
strated follicular disruption by maturing myeloid and erythroid
cells and increased fibrosis (Figure 1E). Livers exhibited periven-
ular neutrophil infiltration (Figure 1F) but lacked the erythroid
and histiocytic infiltrates characteristic of BCR-ABL-induced
CML-like disease (Million et al., 2002). There was modest pulmo-
nary myeloid cell infiltration (Figure 1G), in contrast to the exten-
sive infiltrates and hemorrhages that are the cause of death in
BCR-ABL recipients.
Patients with the ZNF198-FGFR1 fusion usually develop
non-Hodgkin’s lymphoma, predominantly immature T lympho-
blastic lymphoma, in addition to MPD (Inhorn et al., 1995; Mac-
donald et al., 1995). Significantly, all murine ZNF198-FGFR1
recipients also developed T cell lymphoma principally involving
the small intestine. Grossly, the bowel was swollen with promi-
nent serosal nodules accompanied by mesenteric and celiac
lymphadenopathy. Some mice had minimal peripheral lymph
node enlargement but thymuses were normal. Microscopically,
the disease originated in hyperplastic Peyer’s patches, with
disruption of normal follicles and infiltration of submucosal and
intervillous spaces by large cells with immature nuclei and eosin-
ophilic cytoplasm (Figures 2A–2C). This led to the loss of the
entire intestinal epithelium in some areas (data not shown) and
Figure 2. Characterization of ZNF198-FGFR1-induced T lymphoma
A–H: Intestinal T cell lymphoma in ZNF198-FGFR1 recipients. A: H&E-stained
neoplastic Peyer’s patch from small intestine, demonstrating disruption of
normal follicles (bottom) with submucosal and intervillous invasion by malig-
nant lymphoblasts (top). B: H&E-stained frozen section of malignant Peyer’s
patch. C: Closeup view of Peyer’s patch in A, demonstrating infiltration of
sub- and intervillous spaces by immature lymphoblasts with large nuclei
and eosinophilic cytoplasm. D: Anti-Thy-1 immunoperoxidase staining of
Peyer’s patch from B, showing strong immunoreactivity of infiltrating cells. E:
H&E-stained peripancreatic lymph node demonstrating replacement with
lymphoblastic cells. Immunohistochemical staining demonstrated the ma-
jority of the cells were Thy-1 with variable expression of CD8 (data not
shown). F–H: Anti-CD8 (F), anti-B220 (G), and anti-CD4 (H) immunoperoxi-
dase staining of the Peyer’s patch from B. Staining with antibody directed
against GFP showed a similar pattern to D (data not shown). Staining of
Peyer’s patches from control mice demonstrated well-formed follicles that
were GFPand predominantly B220with a peripheral Thy-1/CD4popula-
tion and no staining of submucosal and intervillous areas, while staining of
normal or malignant tissue with isotype control antibody was negative (data
not shown). Scale bars: 100 	m (A, B, D, F, and G), 20 	m (C and E).
I: Flow cytometric characterization of GFP Thy1 cells from diseased mice.
The GFP Thy1 cell population from thymus (Thy), Peyer’s patches (PP),
peripheral lymph nodes (LN), bone marrow (BM), or spleen (Spl) of a normal
Balb/c mouse (nl, top two rows) or two representative mice with ZNF198-
FGFR1-induced EMS-like disease (ZF-1 and ZF-2, bottom four rows) was ana-
lyzed for expression of CD44 and CD25 (blue panels) or CD4 and CD8
(red panels) as described in the Experimental Procedures. The quadrants
comprising the DN1-DN4 populations in normal thymus are indicated by
the respective numbers.
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was the likely cause of death in all ZNF198-FGFR1 recipients.
The lymphomas were Thy-1 with variable expression of CD4
and CD8 but negative for TdT, B220, and myeloid markers
(Figures 2D and 2F–2H, and data not shown), and most had
germline T cell receptor  (TCR) genes (Figure 3A), indicative
of an early T cell phenotype. GFP Thy1 lymphoblastic cells
were also found in enlarged mesenteric and peripancreatic
lymph nodes (Figures 1C and 2E).
Figure 3. ZNF198-FGFR1-induced MPD and T lymphoma arise from a com-
mon multipotential progenitor
A: TCR gene rearrangements in ZNF198-FGFR1-induced T lymphomas. Ge-
nomic DNA from normal liver (nl. liv, lane 1), a control BCR-ABL-transformed
T cell line (con, lane 2), and primary T lymphoma cells from several individual
ZNF198-FGFR1 wild-type (WT, lanes 3–9) and ZNF198-FGFR1 Y766F (lanes
10–17) recipient mice were digested with Bgl II and hybridized with a TCR
probe (Million and Van Etten, 2000). The position of the germline band is
indicated by the arrowhead. Paired samples in lanes 4/5, 8/9, 11/12, 13/
14, and 15/16 are from the same mice. Note germline status of TCR in 4
of 5 ZNF198-FGFR1-induced T lymphomas but clonal rearrangements in all
ZNF198-FGFR1 Y766F-induced lymphomas. Tum, tumor; PP, Peyer’s patch;
m LN, mesenteric lymph node/mass; LN, peripheral lymph node; thy, thymus;
spl, spleen.
B: ZNF198-FGFR1-induced disease is oligo- to monoclonal. Genomic DNA
from the indicated tissues (nomenclature as above; BM  bone marrow)
was analyzed by hybridization with a GFP probe to detect distinct bands
from each proviral integration site. con1 and con2 are control DNAs from
Ba/F3 cell lines each containing a single BCR-ABL provirus, while B-A1 and
B-A2 are spleen DNAs from two different mice with BCR-ABL-induced MPD.
Lanes 6–13 and 14–17 are DNAs from the indicated tissues of mice with
ZNF1980FGFR1 WT- and Y766F-induced disease, respectively. The blot was
stripped and rehybridized with a ZNF198 probe (bottom panels) that detects
a common 3.5 kb band from all proviruses (PV, arrowhead) and the endoge-
nous murine ZNF198 gene (mu ZNF, arrowhead), allowing determination of
the average number of proviruses per cell (copy number) (Li et al., 1999),
which was near single-copy for all mice (corresponding to a value of 1.0).
The bands in lanes 10 and 12, though of similar size, originate from different
integration sites as determined by a blot with EcoRI-digested DNA (data
not shown).
C–G: The cell initiating ZNF198-FGFR1-induced EMS-like disease has multilin-
eage repopulating ability and generates day 12 spleen colonies. Genomic
DNA from purified cells from different hematopoietic lineages from five
different mice with ZNF198-FGFR1-induced EMS-like disease was analyzed
as in B. The same proviral clone was present at near single-copy levels in
peripheral blood neutrophils (PB), peritoneal macrophages (p mφ), spleen
erythroid (spl T119) and B lymphoid (spl B220) cells, and T lymphoma
cells from mesenteric lymph node/mass (m LN) and/or malignant Peyer’s
patch tissue (PP) from one such animal (C). Proviral copy number (bottom
panels) was determined by hybridization with a ZNF198 probe as in B; control
genomic DNA with a single ZNF198-FGFR1 provirus is at the right (con).
Likewise, a common proviral clone (asterisk) was present at high levels in
bone marrow (BM) and peripheral blood myeloid cells, peritoneal macro-
phages, total spleen and splenic B lymphoid and erythroid cells, and Peyer’s
patch and mesenteric T lymphoma cells from another diseased mouse (D),
while one or two proviral clones (asterisks) were shared among myeloid
cells (BM, spleen, p mφ) and T lymphoma from Peyer’s patch, mesenteric
nodes, or intestinal tumor mass (int tum) in two additional mice (E and F).
In a primary mouse with triclonal EMS-like disease (E), the same three clones
were observed in several hematopoietic lineages including peripheral
blood neutrophils, peritoneal macrophages, and spleen T lymphoid cells
(spl Thy-1; this sample is underloaded but has high total proviral content
as determined in the bottom panels). One of the same clones (asterisk)
was found in spleens of two secondary recipients of bone marrow from this
mouse that developed EMS-like disease and succumbed to T lymphoma
(2-1 and 2-2) as well as 8 of 10 day 12 spleen colonies isolated from
additional secondary recipients (lanes 9–18; lane 10 is likely from an ac-
cidental mixture of two colonies). Similar results were observed with 2 ad-
ditional CFU-S donors (data not shown). DNA size markers (in kb) are on
the left.
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To define better the T lymphomas induced by ZNF198- 2 (SH2) domains of Crk (Larsson et al., 1999) and phospholipase
FGFR1, we characterized GFP Thy1 cells from different tis- C-1 (PLC-1) (Mohammadi et al., 1992), respectively, while
sues from diseased mice by flow cytometry (Figure 2I). The the pair of tyrosines (653/654) in the activation loop is required
lymphoma cells were recognizable as CD4CD8 (double nega- for kinase activation (Mohammadi et al., 1996). The function of
tive, DN) cells isolated from Peyer’s patches (PP) that were the other three sites is unknown. We tested the contribution of
predominantly CD44 CD25 with a minor population of CD44 FGFR1 autophosphorylation sites to transformation of Ba/F3
CD25 cells, corresponding to the DN1 and DN2 subsets of and NIH 3T3 cells by ZNF198-FGFR1, using a stringent single-
prothymocytes, respectively. In the thymus, which was of nor- step assay for IL-3-independent and anchorage-independent
mal size and architecture (data not shown), there was a shift in growth, respectively. Transformation was abolished by K514R
the thymocyte population toward CD4 or CD8 single positive or Y653/654F mutations that eliminate kinase activity, and sig-
(SP) cells and a relative paucity of DN and double positive nificantly decreased by mutation of the PLC-1 binding site at
populations, with the DN population composed predominantly Tyr766 but not by individual mutation of the other 4 tyrosines
of DN1 cells. The peripheral lymph nodes of diseased mice were (Figure 4A).
generally normal with exclusively SP T cells, but abnormal GFP To test the role of Tyr766 in leukemogenesis, we trans-
Thy1 DN1-like cells could be found in several tissues, including planted mice with marrow transduced with the ZNF198-FGFR1
bone marrow and spleen, and likely also represented malignant Y766F mutant. Recipients of ZNF198-FGFR1 Y766F-trans-
lymphoma. CD8 cells present in malignant Peyer’s patches
duced marrow survived significantly longer than wild-type
(Figures 2F and 2I) could represent nonmalignant ZNF198-
ZNF198-FGFR1 recipients, while the kinase-inactive ZNF198-FGFR1-expressing CD8 cells with polyclonal TCR rearrange-
FGFR1 K514R mutant did not induce disease (Figures 1A andments and/or a population of malignant CD8 cells that pro-
1B, and Table 1). All ZNF198-FGFR1 Y766F recipients devel-gressed beyond the DN stage without TCR rearrangement.
oped attenuated MPD with lower leukocyte counts comparedThese results confirm that the T lymphomas in ZNF198-FGFR1
to wild-type ZNF198-FGFR1 recipients (Figures 4B and 4C), andrecipients have an early prothymocyte phenotype and demon-
ultimately succumbed to oligoclonal T cell leukemia/lymphomastrate that ZNF198-FGFR1 expression perturbs but does not
(Figure 3B), with circulating GFP Thy-1 lymphoblasts (Figureblock T cell development.
4C) and involvement of the thymus, peripheral lymph nodes
(Figure 4D), spleen, and bone marrow in addition to the smallZNF198-FGFR1-induced EMS-like disease originates
bowel and mesentery (data not shown). The T lymphoma hadfrom a hematopoietic stem/progenitor cell
a more mature phenotype than that induced by wild-typeIn EMS patients, the 8p11 translocation is found in both myeloid
ZNF198-FGFR1, with coexpression of CD4 and CD8 (Figurecells and the T lymphoma, indicating a stem cell origin (Inhorn
4D) and clonal rearrangements of TCR loci (Figure 3A). Theseet al., 1995; Macdonald et al., 1995). The EMS-like disease
induced in mice by ZNF198-FGFR1 was oligo- to monoclonal results demonstrate that FGFR1 Tyr766 contributes to both the
(Figure 3B), and the same proviral clone(s) were detected in myelo- and lymphoproliferative diseases induced in mice by
neutrophils, macrophages, erythroid, B lymphoid, and T lym- ZNF198-FGR.
phoma cells (Figures 3C–3F). In addition, the majority (20/26) We assessed the activation of PLC-1 in primary leukemia
of day 12 spleen colonies generated in secondary transplants cells from diseased mice using Western blotting with antibodies
from several different primary mice with ZNF198-FGFR1- specific for phospho-Tyr783 (Figure 4E). Phosphorylation of
induced EMS-like disease contained the ZNF198-FGFR1 provi- PLC-1 Tyr783 was observed in Ba/F3 cells, T lymphoma cells,
rus (Figure 3G and data not shown), indicating that the EMS- and primary myeloid cells expressing wild-type ZNF198-FGFR1,
like disease arose from a cell with capacity to generate an but was greatly diminished or absent in ZNF198-FGFR1 Y766F-
early multipotential myeloid progenitor, CFU-S12. These results expressing cells (Figure 4E). These results demonstrate that
demonstrate that, similar to BCR-ABL-induced CML-like dis- FGFR1 Tyr766 is required for activation of PLC-1 by ZNF198-
ease (Li et al., 1999), a common hematopoietic stem/progenitor FGR1, and implicate PLC-1 in the pathogenesis of EMS.
cell initiates both the MPD and T lymphoma in recipients of
ZNF198-FGFR-transduced marrow. The EMS-like disease
BCR-FGFR1 induces fulminant CML-likecould be adoptively transferred by transplantation of bone mar-
myeloproliferative disease in micerow and/or spleen from a primary mouse to lethally irradiated
Patients with t(8;22) have fusion of BCR to FGFR1 (Figure 5A)recipients (Figure 1H), with secondary recipients developing
and present with typical CML rather than EMS (Demiroglu et al.,chronic MPD and succumbing after a variable period to T lym-
2001; Fioretos et al., 2001). Interestingly, BCR-FGFR1 inducedphoma arising from a common clone identified in the primary
rapidly fatal CML-like MPD in mice, with significantly shortenedanimal (Figure 3G and data not shown). Collectively, pathologic
survival relative to BCR-ABL (Figure 5B). Recipients of BCR-and molecular analysis of the EMS-like disease induced in mice
FGFR1-transduced marrow developed extreme leukocytosisby ZNF198-FGFR1 reveals a striking similarity to the human
within 14 days posttransplant, while BCR-ABL-induced leuko-8p11 syndrome.
cytosis was delayed by several days (Figures 5C and 5D). Similar
to BCR-ABL, BCR-FGFR1 recipients succumbed to respiratoryThe PLC-1 binding site at FGFR1 Tyr766 contributes
insufficiency with extensive infiltration of spleen, liver, and lungsto MPD and T lymphoma induced by ZNF198-FGFR1
with maturing GFP myeloid cells (Figure 5C) and histopathol-Upon ligand-induced dimerization, FGFR1 undergoes auto-
ogy that was identical to BCR-ABL-induced disease (Million etphosphorylation at seven tyrosine residues in the intracellular
al., 2002), but lacked evidence of lymphoma in the bowel ordomain (Mohammadi et al., 1996) (Figure 1A). Phosphorylated
Tyr463 and Tyr766 serve as binding sites for the Src homology elsewhere (Table 1 and data not shown).
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Bcr-FGFR1 but not ZNF198-FGFR1 binds directly
to Grb2 via Bcr Tyr177
Bcr-Abl binds directly to the SH2 domain of the adaptor protein
Grb2 via a phosphorylated Tyr177 site in Bcr, and mutation of
Tyr177 to Phe severely attenuates BCR-ABL-induced MPD in
mice (Million and Van Etten, 2000). Whereas FGFR1 can bind
Grb2 indirectly via the FRS2/SNT-1 adaptor protein, the
ZNF198-FGFR1 fusion protein lacks the juxtamembrane FRS2
binding site (Ong et al., 2000). In coimmunoprecipitation experi-
ments, we demonstrated that ZNF198-FGFR1 did not bind
Grb2, while Bcr-FGFR1 efficiently coprecipitated with Grb2 (Fig-
ure 5E). To determine whether Bcr Tyr177 was responsible, we
generated a Bcr-FGFR1 Y177F mutant and found that the mu-
tant fusion protein lacked any detectable interaction with Grb2
(Figure 5E). These results demonstrate that fusion of Bcr to
FGFR1 permits this tyrosine kinase to bind directly to Grb2
through Tyr177.
The Grb2 binding site is required for induction
of CML-like MPD by Bcr-FGFR1
To determine the role of the Grb2 binding site in leukemogenesis
by Bcr-FGFR1, we expressed BCR-FGFR1 Y177F in primary
murine bone marrow followed by transplantation into secondary
recipients. Relative to BCR-FGFR1, recipients of BCR-FGFR1
Y177F-transduced marrow had significantly prolonged survival
(Figure 5B and Table 1), developed lower and more stable leuko-
cyte counts (Figure 5D), and ultimately succumbed to intestinal
T lymphoma that was identical to that induced by ZNF198-
FGFR1 (data not shown). Loss of direct Grb2 binding therefore
attenuates the CML-like disease induced by BCR-FGFR1 to
one closely resembling EMS-like disease of ZNF198-FGFR1.
The histopathology of BCR-FGFR1 Y177F-induced disease dif-
fered from both the CML-like and EMS-like syndromes by the
presence of large infiltrates of malignant histiocytes in the livers
of these recipients (Table 1 and data not shown). Bcr-FGFR1
fusion protein was expressed in malignant myeloid progenitors
ZNF198-FGFR1 Y766F; green circles, kinase-inactive (K514R) ZNF198-FGFR1).
Most ZNF198-FGFR1 Y766F recipients exhibited attenuated MPD with leuko-
cyte counts of 10–25 103/	l during the first two months posttransplantation.
C: Wright-Giemsa stain (left panel) and flow cytometric analysis (right pan-
els) of peripheral blood from a recipient of ZNF198-FGFR1 Y766F-transduced
marrow at 92 days posttransplant, with leukocyte count of 63.0  103/	l.
Note the predominance of neutrophils with several immature circulating
lymphoblasts (arrowheads).
D: Wright-Giemsa-stained cytospin preparation (left panel) and flow cyto-
metric analysis (right panels) of malignant lymph node cells from the mouse
in C at time of sacrifice 125 days posttransplant. Note the uniform population
of small to medium-sized lymphoblasts and mitotic figure (arrowhead).
Figure 4. The PLC-1 binding site at FGFR1 Tyr766 contributes to ZNF198- In C and D, normal cells stained with isotype control antibody were 
99%
FGFR1-induced transformation and leukemogenesis in the left lower quadrant (data not shown). Scale bar: 10 	m (C and D).
A: In vitro transformation. The ability of ZNF198-FGFR1 mutants to induce E: PLC-1 phosphorylation in Ba/F3 cells and primary leukemia cells from
IL-3- and anchorage-independent growth in Ba/F3 (left panel) and NIH 3T3 diseased mice. Membrane with protein extracts from Ba/F3 cells (lanes 1–2)
(right panel) cells was determined in a stringent single-step transformation or primary malignant T lymphoma (lanes 3–5) or myeloid cells (lanes 6–8)
assay (see Experimental Procedures). Results (mean SEM) are representa- from diseased mice expressing ZNF198-FGFR1 wild-type (WT, lanes 1, 3, 6,
tive of three independent experiments; the difference in colony number and 7) or ZNF198-FGFR1 Y766F (YF, lanes 2, 4, 5, and 8) was immunoblotted
for the Y766F mutant (asterisks) versus wild-type (Z-F WT) was statistically (IB) with antibodies against phospho-Tyr783 PLC-1 (top panel), total PLC-
significant in both cell types (p  0.05, unpaired t test), while none of the 1 (middle panel), and FGFR1 (bottom panel; ZNF198-FGFR1 appears as
other mutants was significantly different. Vector  MIG virus without an multiple species due to glycosylation). In parallel studies, p210 Bcr-Abl did
oncogene insert. not induce phosphorylation of PLC-1 Tyr783 in Ba/F3 cells (data not shown).
B: Plot of peripheral blood leukocyte count (y axis, logarithmic scale) versus Lane 1 was underloaded as judged by Ponceau S staining, while decreased
time after transplantation (x axis) for the recipients in Figure 1B (red squares, ZNF-FGFR1 Y766F expression in lanes 5 and 8 correlated with the proportion
BCR-ABL: upright magenta triangles, ZNF198-FGFR1; inverted blue triangles, of GFP cells in these samples (data not shown).
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Figure 5. Rapidly fatal CML-like MPD induced in mice by BCR-FGFR1 requires Bcr Tyr177
A: Schematic of (top to bottom) p210 Bcr-Abl, ZNF198-FGFR1, and Bcr-FGFR1 polypeptides, including the Bcr-FGFR1 Grb2 binding site mutant (Y177F).
Domains indicated by gray boxes include the coiled-coil (CC) domain, Tyr177 Grb2 binding site, and Dbl/Cdc42 homology domain in Bcr, the kinase
domain in Abl, MYM repeats and proline-rich (P) dimerization domain in ZNF198, and split kinase domain in FGFR1. The point of fusion is indicated by the
vertical dotted line.
B: Survival curve for recipients of bone marrow transduced with BCR-ABL (red, n  13), BCR-FGFR1 (green, n  20), and the BCR-FGFR1 Y177F mutant
(brown, n  7). The difference in survival between any of the individual arms is highly significant (p  0.0001, Mantel-Cox test).
C: Fulminant CML-like MPD induced by BCR-FGFR1. Wright-Giemsa stain (left panel) and flow cytometric plots (right panels) of peripheral blood of BCR-
FGFR1 recipient 14 days posttransplant with leukocyte count of 240  103/	l. Note the more immature circulating myeloid and erythroid progenitors, with
predominantly GFP Mac-1 cells. Scale bar: 10 	m.
D: Plot of peripheral blood leukocyte count (y axis, logarithmic scale) versus time after transplantation (x axis) for the recipients in B (red squares, BCR-ABL;
upright green triangles, BCR-FGFR1; inverted brown triangles, BCR-FGFR1 Y177F).
E: Grb2 binds Bcr-FGFR1 through Tyr177. Bcr-FGFR1 (B-F), Bcr-FGFR1 Y177F (B-F Y177F), or ZNF198-FGFR1 (Z-F) proteins were expressed in 293 cells and whole
cell extracts (WCL, left) and anti-FGFR1 (middle) and anti-Grb2 (right) immunoprecipitates (IP) immunoblotted (IB) with anti-FGFR1 (top panels) or anti-
Grb2 (bottom panels) antibodies. Note that Bcr-FGFR1, like Bcr-Abl (Li et al., 2001a), induces a lower mobility species of Grb2 that correlates with tyrosine
phosphorylation.
F: Levels of Bcr-FGFR1, Bcr-FGFR1 Y177F, and Bcr-Abl fusion proteins and substrate phosphorylation in primary malignant myeloid progenitors from diseased
mice. Lysates from peripheral blood samples (all 
90% GFP at the time of collection) from three different leukemic mice for each fusion protein were
immunoblotted with antibodies against Bcr (top panel) or pairs of antibodies against Stat5, Gab2, Dok2, or CrkL and their respective tyrosine-phosphorylated
forms (bottom panels). Note that high-level phosphorylation of Stat5 and Dok2 reduces detection of the protein by the pan-reactive antibody. All lanes
were equally loaded as judged by Ponceau-S staining and levels of endogenous Bcr protein (arrowhead). Extracts from normal spleen (nl spleen) and
control extracts from 293 cells expressing BCR-FGFR1 (B-F 293) or Ba/F3 cells expressing BCR-ABL (B-A Ba/F3) are included. Positions of Bcr-FGFR1 (B-F) and
Bcr-Abl (B-A) fusion proteins are indicated by arrowheads; molecular mass markers are on the left.
G: BCR-FGFR1-induced disease is polyclonal. Genomic DNA from spleens of mice with BCR-FGFR1-induced CML-like disease (lanes 6–11) or BCR-FGFR1
Y177F-induced disease (lanes 12–16 and 19) was analyzed for proviral integrations as in Figure 3B. The first five control lanes on the left are as in Figure 3B.
The lower intensity of the proviral bands from B-F Y177F samples correlated with the reduced frequency of GFP cells in these samples (data not shown).
Lanes 17–19 represent lineage analysis from a single B-F Y177F recipient (see text). Positions of DNA size markers (in kb) are to the left.
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at slightly lower levels than Bcr-FGFR1 Y177F or Bcr-Abl (Figure oligoclonal (Figure 3B), suggesting either that ZNF198-FGFR1
alone is insufficient for disease induction, or alternatively that5F, top), demonstrating that the more aggressive MPD induced
by Bcr-FGFR1 was not due to increased expression of this a restricted (and more primitive) population of hematopoietic
stem/progenitor target cells is sensitive to transformation bykinase. We analyzed phosphorylation of several substrates in
the malignant cells using phospho-specific antibodies (Figure ZNF198-FGFR1. Consistent with the latter model, only a small
subset of the many BCR-ABL-transduced clones found in pri-5F, bottom). Stat5 and Gab2 were activated by both Bcr-Abl
and Bcr-FGFR1. Phosphorylation of Stat5 was somewhat higher mary mice with CML-like disease are capable of self-renewal as
measured by generation of CFU-S12 or propagation of leukemiain Bcr-Abl-expressing cells, while efficient phosphorylation of
Gab2 by Bcr-FGFR1 required Tyr177, as previously shown for upon secondary transplantation (Li et al., 1999), whereas the
majority of ZNF198-FGFR1-transduced clones were transplant-Bcr-Abl (Sattler et al., 2002). However, Dok2 and CrkL were
phosphorylated only by Bcr-Abl and were not appreciably acti- able (Figure 3G and data not shown). Further characterization
of the stem cells initiating the two leukemias will be necessaryvated in Bcr-FGFR1-expressing cells. In contrast to the oligoclo-
nal ZNF198-FGFR1-induced EMS-like disease, the diseases in- to establish this hypothesis. On the other hand, ZNF198-FGFR1
alone is not sufficient to induce T lymphoma. ZNF198-FGFR1duced by both BCR-FGFR1 and the Y177F mutant were
polyclonal, similar to BCR-ABL-induced leukemia (Figure 5G). perturbs but does not block thymocyte development, and mice
with EMS-like disease have apparently normal CD4 and CD8In one BCR-FGFR1 Y177F recipient (Figure 5G, lanes 17–20),
the same proviral clones were observed in liver histiocytic sar- single positive ZNF198-FGFR1-expressing T cells in peripheral
lymph nodes. Hence, in contrast to oncogenic transcriptioncoma (liv), spleen T lymphoma (spl Thy1), and bone marrow
neutrophils (BM Gr1), demonstrating a common origin from factors such as constitutively active Notch (Pear et al., 1996),
a block in thymocyte differentiation is not a primary biologicalmultipotential progenitors.
effect of ZNF198-FGFR1 expression, and additional events, ge-
netic and/or epigenetic, must contribute to the development ofDiscussion
T lymphoma in these mice.
While the FGFR1 tyrosine kinase domain is an excellentIf the future of cancer therapeutics lies in molecularly targeted
drugs, a major focus will be on the identification, validation, and drug target, monotherapy of EMS with an FGFR1 kinase inhibitor
is likely to lead eventually to drug resistance, as is the case withpreclinical evaluation of candidate drug targets for the many
different forms of cancer. Much interest has centered on dysreg- imatinib for CML (Shah et al., 2002). Identification of the critical
signaling pathways downstream of ZNF198-FGFR1 that con-ulated tyrosine kinases in leukemia because, by analogy with
Bcr-Abl, they are attractive potential drug targets. In the murine tribute to leukemogenesis is important because simultaneous
inhibition of these pathways may complement kinase inhibitorretroviral bone marrow transduction/transplantation model, sev-
eral dysregulated tyrosine kinases do not faithfully reproduce therapy. We initially focused on the role of FGFR1 autophos-
phorylation sites and used transformation of Ba/F3 and 3T3the human leukemia from which they were isolated. Tel-Jak2
induces simultaneous myelo- and lymphoproliferative disease cells as a surrogate assay to prioritize the selection of different
autophosphorylation site mutants for leukemogenesis studies.in mice that is not observed in patients with t(9;12) (Schwaller
et al., 1998). The NPM-ALK fusion protein induces diffuse large Contrary to an initial report (Ollendorff et al., 1999) but in agree-
ment with subsequent studies (Smedley et al., 1999; Xiao et al.,B cell lymphoma in mice but not the anaplastic lymphoma char-
acteristic of t(2;5) non-Hodgkin’s lymphoma patients (Kuefer et 2000), we found wild-type ZNF198-FGFR1 capable of inducing
both IL-3-independent survival and proliferation of Ba/F3 cells.al., 1997). The FIP1L1-PDGFRA fusion kinase (Cools et al., 2003)
induces MPD in mice, not the hypereosinophilic syndrome found Although all kinase-active ZNF198-FGFR1 mutants induced
proliferation of Ba/F3 cells in liquid culture (data not shown), inin patients. In contrast, we demonstrated here that the ZNF198-
FGFR1 fusion oncogene of the (8;13) translocation induces he- a stringent colony-forming assay, mutation of FGFR1 Tyr766
impaired transformation of Ba/F3 cells by ZNF198-FGFR1. Thematologic disease in mice that very closely resembles human
EMS. Recipients of ZNF198-FGFR1-transduced bone marrow Y766F mutation has also been reported to abolish IL-3-indepen-
dent survival of Ba/F3 cells and attenuate myeloproliferativeuniformly develop MPD and T lymphoma that arises from a
common hematopoietic stem/progenitor cell. Similar to patients disease induced by the related FOP-FGFR1 fusion (Guasch et
al., 2001, 2004). In FGF receptor-1, the Y766F mutation abol-with t(8;22), the BCR-FGFR1 oncogene induced very rapid
CML-like disease in the same mouse model system. Hence, ishes FGF-induced phosphaditylinositol hydrolysis but has no
effect on mitogenesis (Mohammadi et al., 1992). However, FGFthe distinct human leukemia syndromes associated with these
dysregulated tyrosine kinases are faithfully and accurately mod- receptors that lack FRS2 association and activation are more
dependent on Tyr766 for signaling (Lin et al., 1998), suggestingeled in mice. Our results implicate the ZNF198-FGFR1 and Bcr-
FGFR1 tyrosine kinases as the direct cause of their respective that the ZNF198-FGFR1 fusion protein may also rely on this
site for generating oncogenic signals. In support of this hypothe-diseases and validate both as drug targets. Furthermore, while
the reciprocal FGFR1-ZNF198 fusion transcript is expressed in sis, the Y766F mutation significantly attenuated both the MPD
and T lymphoma induced in mice by ZNF198-FGFR1 and abol-some patients with t(8;13) EMS disease (Popovici et al., 1998),
our findings argue that neither the respective reciprocal translo- ished activation of PLC-1 in primary leukemia cells by the
fusion protein. The T lymphomas that eventually developed incation products nor haploidy for either the ZNF198 or FGFR1
genes are essential for leukemogenesis. ZNF198-FGFR1 Y766F recipients had a more mature phenotype
that is similar to those induced by BCR-ABL Y177F, and mayBCR-ABL and BCR-FGFR1 induce polyclonal myeloprolifer-
ative disease in mice, which implies that the expression of the arise from a distinct T lymphoid progenitor (Million and Van
Etten, 2000). Our results identify PLC-1 and its downstreamfusion kinase alone is sufficient to induce leukemia (Li et al.,
1999). In contrast, the MPD induced by ZNF198-FGFR1 was effectors including the protein kinase C family as additional
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ern blot analysis of cells transduced with serial dilutions of virus. All viraltargets for therapy in EMS, and inhibitors of these enzymes can
stocks were matched for titer and gave equivalent transduction efficiencybe tested, alone or in combination with FGFR1 inhibitors, in our
in 3T3 cells and primary murine bone marrow (data not shown). Bone marrowmodel.
transduction and transplantation was carried out using 5-fluorouracil-treated
The Bcr-FGFR1 kinase binds Grb2 and induced fulminant (200 mg/kg) male donor and lethally irradiated (900 cGy) female recipient
CML-like MPD in recipient mice, demonstrating that the identity Balb/c mice (Taconic Farms, Germantown, Maryland) exactly as described
of the NH2-terminal partner protein fused to FGFR1 can dramati- (Li et al., 1999; Million et al., 2002). For secondary transplantation, 3  106
viable bone marrow cells or an equal mixture of marrow and splenocytescally alter the leukemia phenotype. The Bcr Y177F mutation
from primary diseased mice were transferred by tail vein injection into lethallyabolished Grb2 association and greatly attenuated the MPD
irradiated Balb/c recipient mice.induced by Bcr-FGFR1 to a more chronic illness resembling
EMS, including intestinal T lymphoma. Direct binding of Grb2 to Analysis of diseased mice
Bcr-FGFR1 therefore explains the aggressive CML-like disease Premoribund mice were sacrificed and analyzed by cytospin and histopathol-
induced by this fusion kinase. It has recently been shown that ogy as described (Li et al., 1999; Million and Van Etten, 2000). For immunohis-
tochemistry, tissues were embedded in OCT compound, frozen in 2-meth-the Gab2 adaptor protein is recruited to Bcr-Abl Tyr177 through
ylbutane, and cryostat sections fixed in acetone and stained with horseradishinteraction with Grb2, which is required for efficient phosphory-
peroxidase (HRP)-conjugated monoclonal antibodies against Thy-1.2, CD4,lation of Gab2 and for transformation of hematopoietic cells by
CD8, B220, CD11b (all from Pharmingen, Carlsbad, California), TdT (Su-Bcr-Abl through activation of the phosphatidylinositol 3-kinase
pertechs, Bethesda, Maryland), and GFP (Santa Cruz Biotechnology, Santa
and ERK/MAPK pathways (Sattler et al., 2002). Likewise, we Cruz, California). HRP activity was detected by DAB reaction (DakoCytoma-
found that activation of Gab2 by Bcr-FGFR1 required Tyr177, tion, Carpinteria, California) and sections counterstained with hematoxylin.
suggesting that Gab2 is probably the critical partner for Grb2 For flow cytometry, cell populations were stained with PE-conjugated anti-
bodies to hematopoietic cell surfaces antigens (all from Pharmingen) anddownstream of Bcr-FGFR1 as well as Bcr-Abl. As a corollary,
analyzed on a FACScalibur flow cytometer (Becton Dickinson, Franklinour studies predict that Gab2 may be required for leukemogene-
Lakes, New Jersey). For analysis of T cell development, the GFP Thy1 orsis by BCR-FGFR1 but not ZNF198-FGFR1, and the availability
GFP CD19 CD11b CD8a populations from various tissues were co-
of Gab2-deficient mice (Gu et al., 2001) will allow this hypothesis stained with CD4-PE and CD8a-APC or CD25-PE and CD44-APC antibodies
to be tested directly. The tyrosine kinase portion of the fusion (Pharmingen), respectively.
protein can also influence leukemia signaling and phenotype.
The signaling proteins Dok2 and CrkL were phosphorylated by Lineage and CFU-S12 analysis and Southern blotting
Purification of neutrophils and spleen erythroid progenitors and B lympho-Bcr-Abl but not Bcr-FGFR1, perhaps due to direct physical
cytes employed lineage-specific monoclonal antibodies and magnetic beadsinteractions with Abl (Druker et al., 1992; Ren et al., 1994), while
(Miltenyi Biotec, Auburn, California), while peritoneal or bone marrow macro-PLC-1 was bound and activated by the FGFR1 fusion kinases
phages were isolated by adherence, as described (Li et al., 1999; Million et
but not Bcr-Abl. Previous studies with FOP-FGFR1 have also al., 2002). T lymphoma cells were obtained from mesenteric lymph nodes.
implicated the MAPK and Akt/mTOR pathways in transformation The purity of the selected populations was assessed by Wright-Giemsa
(Guasch et al., 2001). Intestinal T lymphoma is never observed staining of cytospin preparations and in some cases by FACS analysis, and
only those samples with 80% purity used for Southern blot analysis. Dayin recipients of BCR-ABL-transduced marrow but is found in
12 spleen colonies were isolated from secondary recipients of bone marrowBCR-FGFR1 Y177F recipients, suggesting that the FGFR1 ki-
from primary mice with ZNF198-FGFR1-induced disease as described (Mil-nase domain is required specifically for this disease, although
lion et al., 2002). Genomic DNA was prepared, digested with BglII, and
identification of the precise signaling pathways involved will hybridized with a radioactive probe from the GFP gene to detect distinct
require further studies. proviral integration events, then stripped and reprobed with a human ZNF198
In conclusion, our results demonstrate that CML and EMS, probe that detects a common 3.5 kb fragment from all proviruses and allows
determination of total proviral content of each sample, as described (Li etdistinct human leukemia syndromes associated with different
al., 1999).fusion tyrosine kinases, are accurately and quantitatively mod-
eled in mice and implicate different signaling pathways originat-
Ba/F3 and NIH3T3 cell transformationing from both the kinase domain and the NH2-terminal fusion Transformation of interleukin-3 (IL-3)-dependent Ba/F3 cells to IL-3-indepen-
partner in their pathogenesis. This model system should be dent growth in soft agar and NIH 3T3 fibroblasts to anchorage-independent
valuable for further study of the molecular pathophysiology of growth was performed essentially as described (Li et al., 2001a). Briefly,
EMS and for developing and testing targeted therapies for this cells were transduced with retrovirus coexpressing ZNF198-FGFR1 or the
indicated point mutants with GFP, cultured for 24 hr, then washed anddisease.
plated in triplicate in 0.6% agar in medium with 10% serum but without
supplemental growth factors. Colonies were counted 7 or 21 days later forExperimental procedures
Ba/F3 and 3T3 cells, respectively, and mean colony number normalized
by the percentage of GFP cells in the original transduced population asDNA constructs
determined by flow cytometry (3%–10% for Ba/F3 cells and 30%–40% forcDNAs for ZNF198-FGFR1 (Reiter et al., 1998) and BCR-FGFR1 (Demiroglu
3T3 cells).et al., 2001) were introduced into the EcoRI site of the MSCV-IRES/GFP
(MIG) retroviral vector (Schwaller et al., 1998), allowing coexpression of the
Western blotting and coimmunoprecipitationfusion tyrosine kinase and enhanced green fluorescent protein via an internal
Lysates from Ba/F3 cells stably expressing ZNF198-FGFR1 or the Y766Fribosome entry site. In ZNF198-FGFR1, Lys514 to Arg and Tyr to Phe muta-
mutant were prepared in RIPA buffer while lysates from primary malignanttions at positions 463, 583, 585, 653/654, 730, and 766 (amino acids are
T lymphoma or myeloid cells from diseased mice were prepared by directnumbered according to their position in normal FGFR1) in FGFR1 were
boiling in sample buffer, then analyzed by SDS-PAGE and immunoblottinggenerated by PCR and confirmed by DNA sequencing.
with polyclonal rabbit antibodies as described (Million et al., 2002). Antibod-
ies specific for total and phospho-Tyr783 PLC-1, total and phospho-Tyr351Bone marrow transduction and transplantation
High-titer, replication-defective ecotropic retroviral stocks were generated p56Dok2, phospho-Tyr207 CrkL, and phospho-Tyr452 Gab2 were obtained
from Cell Signaling Technology (Beverly, Massachusetts), while antibodiesby transient transfection of 293 cells using the kat system as described
(Million et al., 2002), and titered by flow cytometric and genomic DNA South- to Bcr, FGFR1, Stat5, and CrkL were from Santa Cruz Biotechnology. Anti-
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lner, U., et al. (2002). Hematologic and cytogenetic responses to imatinibbodies against Gab2 were the kind gift of Dr. Haihua Gu (Beth Israel Deacon-
mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645–652.ess Medical Center, Boston, Massachusetts). Coimmunoprecipitation of
Grb2 and Bcr-FGFR1 was performed as described (Million and Van Etten, Kuefer, M.U., Look, A.T., Pulford, K., Behm, F.G., Pattengale, P.K., Mason,
2000). D.Y., and Morris, S.W. (1997). Retrovirus-mediated gene transfer of NPM-
ALK causes lymphoid malignancy in mice. Blood 90, 2901–2910.
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